The creation of novel anticancer drugs is the aim of this research. Our decision about which compounds to synthesis was aided by docking studies. Using data from the protein databank and refinement from BIOVIA discovery, the protein structure of AGF183 (PDB5IZQ). It was subjected to molecular docking investigations using PyRx 0.8 Autodock Vina software. following the creation of a novel sequence of thiophene-2,5-carbohydrazide. Final chemicals such as thiophene-2,5-carbohydrazide derivatives (G1 and G2) are produced via the Japp Klinegmann process. This reaction makes it possible to produce Schiff bases without any problems. Diethylthiophene-2,5-dicarboxylate was reacted with an aromatic diazonium salt to create the final products. When compared to the reference drug imatinib, the synthesized compounds exhibited the strongest anticancer effect. The study conducted on MCF-7 cell line demonstrated that compounds G1 and G2 demonstrated the most potent anticancer effect. Compared to the reference value of imatinib, which is 52.77 µg/ml and has G1 and G2 docking scores of -8.8, -8.6, and the standard medication methotrexate (-11.87 kcal/mol), their IC50 values were 46.52 µg/ml and 50 µg/ml. On base of characterization results above show that it Japp Klinegmann Synthesis method is useful for synthesis of thiophene hydrazone derivatives and its findings imply that the MCF-7 cells, which are utilized to potential treatment for human breast cancer.